On this page
Back to topWest Pharmaceutical Services WST
West Pharmaceutical Services is the 335th largest S&P 500 company by market cap, worth $28.8 billion. Its board has 14 directors, 10 of them independent. 8 other officers are on file. At 30 Jun 2026, Vanguard was its largest institutional holder, with 13.3% of the company.
- Chair
- Eric Mark Green
- Sector
- Health CareHealth Care Supplies
- Headquarters
- Exton, Pennsylvania
- Founded
- 1923
- Market cap
- $28.8B
- 335th largest, 11 Nov 2026 close
- Price to sales
- 9.4
- Market cap over revenue
- Per employee
- $2.7M
- Market cap over employees
- Connections
- 4
- Companies sharing people
Financials
Latest quarter
Q2 2026 figures from West Pharmaceutical Services' earnings release.
Filed 23 Jul 2026
- Revenue
- $872M
- Up 14% year over year
- Net income
- $154M
- Up 17% year over year
- Diluted EPS
- $2.15
- Up 18% year over year
- Operating income
- $179M
- Up 17% year over year
Reported figures
Figures from the release, against the same period a year earlier.
| Figure | Value | Change |
|---|---|---|
| Net sales | $872M | +14% |
| Diluted EPS | $2.15 | +18% |
| Adjusted-diluted EPS | $2.37 | +29% |
| Operating cash flow | $214M | - |
| Capital expenditures | $86M | - |
| Free cash flow | $128M | - |
| Gross profit | $329M | +20% |
| Operating profit | $179M | +17% |
| Net income | $154M | +17% |
| Gross profit margin | 37.7% | +2.0 pts |
| Reported Operating Profit Margin | 20.5% | +0.4 pts |
| Adjusted Operating Profit | $197M | +27% |
| Adjusted Operating Profit Margin | 22.6% | +2.3 pts |
| Figure | Value | Change |
|---|---|---|
| Proprietary Products net sales | $723M | +17% |
| West Vantage net sales | $150M | +2.0% |
| Proprietary Products gross profit | $308M | +24% |
| West Vantage gross profit | $21M | -17% |
| Proprietary Products operating profit | $212M | +31% |
| West Vantage operating profit | $13M | -28% |
| HVP Components net sales | $424M | +19% |
| HVP Delivery Devices net sales | $131M | +30% |
| Standard Products net sales | $167M | +2.4% |
| Biologics net sales | $375M | +30% |
| Pharma net sales | $205M | +3.3% |
| Generics net sales | $143M | +6.9% |
| Americas net sales | $389M | +11% |
| Europe, Middle East, Africa net sales | $400M | +14% |
| Asia Pacific net sales | $84M | +25% |
| Figure | Value | Change |
|---|---|---|
| Net sales guidanceFull-year 2026 outlook | $3.4B | - |
| Adjusted-diluted EPS guidanceFull-year 2026 outlook | $8.95 | - |
| Net sales guidanceQ3 2026 outlook | $828M | - |
| Adjusted-diluted EPS guidanceQ3 2026 outlook | $2.19 | - |
| Figure | Value | Change |
|---|---|---|
| Share repurchases | $454M | - |
| Dividend declaredQ3 2026 | $0.22 | - |
Financial history
Twelve months to 30 Sep 2026, from West Pharmaceutical Services' quarterly filings.
Quarters since Dec 2021
- Revenue
- $3.4B
- Up 13% on the year before
- Net income
- $639M
- 18.8% of revenue
- Free cash flow
- $453M
- Operating cash flow less capital spending
- P/E
- 45.0
- Market cap over net income
Quarterly results
Each quarter's revenue, net income and free cash flow.
Dec 2021 to Sep 2026
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $875M | $214M |
| Jun 2026 | $872M | $154M |
| Mar 2026 | $845M | $139M |
| Dec 2025 | $805M | $132M |
| Sep 2025 | $805M | $140M |
| Jun 2025 | $767M | $132M |
| Mar 2025 | $698M | $90M |
| Dec 2024 | $749M | $130M |
| Sep 2024 | $747M | $136M |
| Jun 2024 | $702M | $111M |
| Mar 2024 | $695M | $115M |
| Dec 2023 | $732M | $137M |
| Sep 2023 | $747M | $161M |
| Jun 2023 | $754M | $155M |
| Mar 2023 | $717M | $140M |
| Dec 2022 | $709M | $103M |
| Sep 2022 | $687M | $121M |
| Jun 2022 | $771M | $189M |
| Mar 2022 | $720M | $174M |
| Dec 2021 | $731M | $148M |
Per employee
Twelve months to 30 Sep 2026, over 10,800 employees in West Pharmaceutical Services' latest 10-K.
- Revenue
- $315K
- Operating profit
- $72K
- 23.0% of revenue
- Net income
- $59K
- 18.8% of revenue
Revenue breakdown
West Pharmaceutical Services' $875M of revenue, as its quarterly report splits it. Parts that are not a business, such as sales between segments, can be negative.
Quarter to Sep 2026
| Split by | Part | Revenue |
|---|---|---|
| Segment | Proprietary Products | $729M |
| Segment | West Vantage | $146M |
West Pharmaceutical Services' market cap since December 2008
Weekly, up to 6 Nov 2026
| Week ending | Market cap |
|---|---|
| 6 Nov 2026 | $27.9B |
| 26 Dec 2025 | $19.7B |
| 27 Dec 2024 | $24.1B |
| 29 Dec 2023 | $26.1B |
| 30 Dec 2022 | $17.4B |
| 31 Dec 2021 | $34.7B |
| 25 Dec 2020 | $20.9B |
| 27 Dec 2019 | $11.2B |
| 28 Dec 2018 | $7.1B |
| 29 Dec 2017 | $7.3B |
| 30 Dec 2016 | $6.2B |
| 25 Dec 2015 | $4.4B |
| 26 Dec 2014 | $3.8B |
| 27 Dec 2013 | $3.4B |
| 28 Dec 2012 | $1.9B |
| 30 Dec 2011 | $1.3B |
| 31 Dec 2010 | $1.4B |
| 25 Dec 2009 | $1.3B |
| 26 Dec 2008 | $1.2B |
Download West Pharmaceutical Services' data as JSON, with the weekly market caps in billions of dollars from 5 Dec 2008.
Board and leadership
Board and officers
4 people here also hold roles at other S&P 500 companies.
Board from the proxy filed 12 Mar 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (14) | |||||
| Eric Mark GreenChair and CEONot independent · since 2015Also at Ecolab | |||||
| Mark A. ButhmanDirectorIndependent · since 2011 · CompensationFormer Executive Vice President & Chief Financial Officer, Kimberly-Clark CorporationAlso at IDEX | |||||
| William F. FeeheryDirector | |||||
| William F. Feehery, Ph.D.DirectorIndependent · since 2012 · AuditFormer Chief Executive Officer, Certara, Inc. | |||||
| Robert F. FrielLead Independent DirectorIndependent · since 2020 · Nominating and Corporate GovernanceRetired Chair, President & Chief Executive Officer, PerkinElmer, Inc. (now Revvity, Inc.)Also at Xylem | |||||
| Janet Brutschea HaugenDirectorIndependent · since 2024 · Audit (chair)Retired Chief Financial Officer, Unisys CorporationOther boards: Bentley Systems and NCR Voyix | |||||
| Molly JosephDirectorIndependent · since 2021 · Compensation (chair), Nominating and Corporate GovernanceFormer Chief Executive Officer, UnitedHealthcare GlobalOther boards: Lumexa Imaging, Inc. | |||||
| Deborah L. KellerDirectorIndependent · since 2017 · Nominating and Corporate Governance (chair), CompensationFormer Chief Executive Officer, Covance Drug Development | |||||
| Goldman Myla LaiDirector | |||||
| Myla P. Lai-Goldman, M.D.DirectorIndependent · since 2014 · AuditChair & Former Chief Executive Officer & President, GeneCentric Therapeutics, Inc.Other boards: Quanterix Corporation | |||||
| Stephen H. LockhartDirector | |||||
| Stephen H. Lockhart, M.D., Ph.D.DirectorIndependent · since 2022 · CompensationFormer Chief Medical Officer, Sutter HealthOther boards: Molina Healthcare and National Research Corporation Health | |||||
| Douglas A. MichelsDirectorIndependent · since 2011 · Audit, Nominating and Corporate GovernanceRetired President & Chief Executive Officer, OraSure Technologies, Inc. | |||||
| Paolo PucciDirectorIndependent · since 2016 · AuditRetired Chief Executive Officer, ArQule, Inc.Other boards: Replimune Group Inc. | |||||
| Officers (8) | |||||
| Robert W. McMahonSVP & Chief Financial OfficerLast filed 12 Aug 2026 | |||||
| Shane Alden CampbellSVP, Proprietary SegmentLast filed 14 May 2026 | |||||
| Annette F. FavoriteSr. VP & Chief HR OfficerLast filed 15 Sep 2026 | |||||
| Norman D. Finch Jr.SVP, GC & Corporate SecretaryLast filed 3 Mar 2026 | |||||
| Michel LagardePresident and CEOAlso at Vertex PharmaceuticalsLast filed 10 Sep 2026 | |||||
| Rodolphe Jean PoussotSVP, Strategy & Corporate DevLast filed 3 Mar 2026 | |||||
| Chad WintersVP, Chief Accounting OfficerLast filed 29 Apr 2026 | |||||
| Charles WitherspoonVP & TreasurerLast filed 23 Feb 2026 | |||||
Companies that share people with West Pharmaceutical Services
Each person's title here, then at the other company.
- Ecolab ECL
- Eric Mark Green: Chair and CEO here, Director there
- IDEX IEX
- Mark A. Buthman: Director here, Director there
- Vertex Pharmaceuticals VRTX
- Michel Lagarde: President and CEO here, Director there
- Xylem XYL
- Robert F. Friel: Lead Independent Director here, Chair there
Owners and trading
Largest institutional holders
Each fund group's share of West Pharmaceutical Services. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 10 Nov 2025 to 10 Nov 2026
Directors and officers sold $6.6 million of stock in 6 sales and made no open-market purchases in the 12 months to 10 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 15 Sep 2026Sale | Annette F. FavoriteSr. VP & Chief HR Officer | $921K |
| 14 Sep 2026Sale | Annette F. FavoriteSr. VP & Chief HR Officer | $888K |
| 11 Sep 2026Sale | Annette F. FavoriteSr. VP & Chief HR Officer | $863K |
| 8 Sep 2026Sale | Annette F. FavoriteSr. VP & Chief HR Officer | $2.8M |
| 27 Apr 2026Sale | Annette F. FavoriteSr. VP & Chief HR Officer | $860K |
| 27 Apr 2026Sale | Chad WintersVP, Chief Accounting Officer | $269K |
Trades by members of Congress and officials
Trades members of Congress and senior executive branch officials disclosed, including their families'. Amounts are filed as ranges.
Trades from 30 Oct 2023 to 30 Oct 2026
6 people disclosed 8 purchases and 8 sales of West Pharmaceutical Services stock since October 2023.
| Date | Member or official | Amount |
|---|---|---|
| 30 Jan 2026 | Arjun ModyDeputy Commissioner · Sold | $1K to $15K |
| 29 Jan 2026 | Rohit KhannaHouse, D-CA · Bought | $1K to $15K |
| 22 Jul 2025 | Lisa McClainHouse, R-MI · Sold | $1K to $15K |
| 17 Jun 2025 | Lisa McClainHouse, R-MI · Bought | $1K to $15K |
| 9 Jun 2025 | Stephen I MiranGovernor · Sold | $15K to $50K |
| 19 May 2025 | Rohit KhannaHouse, D-CA · Bought | $1K to $15K |
| 23 Apr 2025 | Rohit KhannaHouse, D-CA · Bought | $1K to $15K |
| 8 Apr 2025 | Rob BresnahanHouse, R-PA · Sold | $1K to $15K |
| 12 Mar 2025 | Rohit KhannaHouse, D-CA · Sold | $1K to $15K |
| 25 Feb 2025 | Rob BresnahanHouse, R-PA · Bought | $1K to $15K |
Showing 10 of 16 trades
Workforce and hiring
Workforce
Headcount at 31 Dec 2025
- Employees
- 10,800
Employees, last 10 fiscal years
Up 17% in five years, from 9,200 in 2020 to 10,800 in 2025.
As of December 31, 2025, we employed approximately 10,800 people, excluding contractors and temporary workers, in our operations throughout the world.
Open roles
Jobs listed on West Pharmaceutical Services' careers site, each counted once.
Daily, up to 10 Nov 2026
- Open roles
- 246
- On 10 Nov 2026
- Change
- +14
- Up 6.0% since 3 Nov 2026
- Top function
- Operations & Supply Chain
- 59% of open roles
- Remote
- 0%
- 24% do not say
Open roles in detail
27 Oct 2026 to 10 Nov 2026
Most are in the US (54%), then Germany and India.
| Role | Posted |
|---|---|
| Sr. Controls EngineerKinston, NC, US, 28504 | 10 Nov 2026 |
| Assoc. Engineer, Technical TrainingJurong, SG, SG | 9 Nov 2026 |
| Associate Specialist, TCS, NAExton, PA, US, 19341 | 9 Nov 2026 |
| Manager, Finance TransformationDublin, L, IE; Exton, PA, US, 19341 | 9 Nov 2026 |
| MetrologistCidra, PR, US, 00739 | 9 Nov 2026 |
| Production PlannerJurong, SG, SG | 9 Nov 2026 |
| Senior Associate, ProcurementExton, PA, US, 19341 | 9 Nov 2026 |
| Warehouse AttendantCidra, PR, US, 00739 | 9 Nov 2026 |
| Day | Open roles |
|---|---|
| 10 Nov 2026 | 246 |
| 3 Nov 2026 | 232 |
| 2 Nov 2026 | 231 |
| 1 Nov 2026 | 230 |
| 31 Oct 2026 | 230 |
| 30 Oct 2026 | 241 |
| 29 Oct 2026 | 233 |
| 28 Oct 2026 | 233 |
| 27 Oct 2026 | 230 |
WARN layoff notices
Notices filed under West Pharmaceutical Services' own name or a subsidiary's listed in its 10-K.
Notices from 12 Nov 2023 to 12 Nov 2026
West Pharmaceutical Services filed 1 notice covering 98 workers since November 2023.
| Notice | Place | Workers |
|---|---|---|
| 3 Sep 2026 | Scottsdale, AZ | 98 |
Timeline
Leadership changes, layoffs and insider sales
12 Nov 2024 to 12 Nov 2026; insider sales from 10 Nov 2025
5 departures and 7 appointments of directors and officers, WARN layoff notices on 1 day and 1 large insider sale in the last two years.
Insider sales of $1 million or more, and the largest tenth of West Pharmaceutical Services' insider sales.
Events, newest first
- 8 Sep 2026 Annette F. Favorite sold $2.8MSr. VP & Chief HR Officer
- 3 Sep 2026 98 workers in Scottsdale, AZWARN notice
- 31 May 2026 Robert F. Friel appointedChair of the Board, effective 31 Aug 2026
- 31 May 2026 Michel Lagarde appointedMember of the Board, effective 31 Aug 2026
- 31 May 2026 Michel Lagarde appointedPresident and Chief Executive Officer, effective 31 Aug 2026
- 9 Mar 2026 Eric M. Green retiredChair of the Board of Directors, effective 31 Aug 2026
- 9 Mar 2026 Eric M. Green retiredPresident and Chief Executive Officer, effective 31 Aug 2026
- 11 Sep 2025 Kimberly Banks MacKay leftSenior Vice President, General Counsel, and Corporate Secretary
Showing 8 of 14 events
| Date | Event | Filing |
|---|---|---|
| 8 Sep 2026 | Annette F. Favorite sold $2.8MSr. VP & Chief HR Officer | Form 4 |
| 3 Sep 2026 | 98 workers in Scottsdale, AZWARN notice | WARN |
| 31 May 2026 | Robert F. Friel appointedChair of the Board, effective 31 Aug 2026 | 8-K |
| 31 May 2026 | Michel Lagarde appointedMember of the Board, effective 31 Aug 2026 | 8-K |
| 31 May 2026 | Michel Lagarde appointedPresident and Chief Executive Officer, effective 31 Aug 2026 | 8-K |
| 9 Mar 2026 | Eric M. Green retiredChair of the Board of Directors, effective 31 Aug 2026 | 8-K |
| 9 Mar 2026 | Eric M. Green retiredPresident and Chief Executive Officer, effective 31 Aug 2026 | 8-K |
| 11 Sep 2025 | Kimberly Banks MacKay leftSenior Vice President, General Counsel, and Corporate Secretary | 8-K |
| 21 Jul 2025 | Bernard Birkett retiredSenior Vice President & Chief Financial Officer, effective 4 Aug 2025 | 8-K |
| 21 Jul 2025 | Bernard Birkett appointedSenior Advisor to our Chief Executive Officer, effective 4 Aug 2025 | 8-K |
| 21 Jul 2025 | Robert McMahon appointedSenior Vice President & Chief Financial Officer, effective 4 Aug 2025 | 8-K |
| 22 Apr 2025 | Shane Campbell appointedSenior Vice President, Chief Proprietary Segment Officer, effective 5 May 2025 | 8-K |
| 7 Mar 2025 | Cindy Reiss-Clark leftSenior Vice President and Chief Commercial Officer | 8-K |
| 9 Dec 2024 | Janet Haugen appointedBoard of Directors | 8-K |